Latest news with #AutonomixMedical
Yahoo
23-05-2025
- Business
- Yahoo
AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech
Autonomix Medical, Inc. AMIX recently announced that it has been granted a key U.S. patent for its innovative catheter-based platform designed to sense and differentiate nerve signals in real-time. This technology represents a significant leap forward in the field of neuromodulation, with the potential to enhance treatment precision across a wide range of chronic conditions, including cancer and pain management. The platform enables both sensing and stimulation of nerves through a single device. With the burden of chronic diseases and the complexity of nerve-related disorders posing ongoing challenges in modern medicine, Autonomix's patented technology addresses a critical need for more accurate, targeted therapies. Its ability to map nerve activity in real-time during procedures may reduce the risk of nerve damage, improve patient outcomes, and offer physicians a powerful new tool in both diagnostics and treatment. Following the announcement, shares of the company traded flat till yesterday's closing. Shares of the company have lost 52.1% in the year-to-date period compared with the industry's 7.7% decline. The S&P 500 has gained 0.3% in the same time frame. The patent approval significantly strengthens AMIX's long-term business by securing exclusive rights to its innovative nerve-sensing and stimulation technology. This positions the company as a first-mover in a high-demand market, enabling it to pursue commercialization, licensing, and strategic partnerships with greater confidence. The technology's potential applications across chronic pain, cancer, and other nerve-related conditions open doors to large, underserved markets. Additionally, the patent enhances investor confidence, protects R&D investments, and improves the company's overall valuation and long-term growth prospects. AMIX currently has a market capitalization of $4.4 million. It has a price-to-book ratio of 0.5X, which is lower than the industry's 2.30X. Image Source: Zacks Investment Research AMIX achieved a major milestone with the issuance of U.S. Patent No. 12,257,071 ('071 patent). Titled Controlled sympathectomy and micro-ablation systems and methods, the patent covers Autonomix's novel catheter-based technology, which combines real-time nerve mapping with radiofrequency (RF) ablation. This integrated system is designed to identify and ablate overactive nerves within the peripheral nervous system using a minimally invasive approach. The technology enables more precise and effective treatments for a range of neurological disorders, including chronic pain and hypertension, offering a promising alternative to traditional, less targeted methods. A key highlight of the '071 patent is the set of advanced features that make Autonomix's technology stand out in the field of nerve-targeted treatments. The system features tiny, flexible 'microfingers' with built-in sensors that monitor a patient's physiological responses in real time. It also enables doctors to sense, map, stimulate, treat, and confirm the success of a procedure, all using a single integrated device. At the heart of the platform is a first-of-its-kind catheter-based microchip antenna that can detect and distinguish nerve signals with far greater accuracy than existing technologies. Once the problematic nerves are identified, Autonomix uses its own RF ablation method to precisely deactivate them. This 'sense, treat, and verify' approach offers a major improvement over traditional methods like opioids or alcohol injections, which often provide only temporary relief and come with serious side effects. Looking ahead, Autonomix plans to submit an IDE and initiate U.S. clinical trials in 2025, targeting pancreatic cancer pain as its first commercial indication. Currently, AMIX carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite's 10.5% growth. AngioDynamics' earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Autonomix Medical, Inc. (AMIX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Associated Press
14-05-2025
- Business
- Associated Press
Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event
Live webcast followed by an interactive Q&A session on Thursday, May 22ndat 4:00 PM ET Access the eventhere THE WOODLANDS, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ('Autonomix' or the 'Company'), a medical device company focused on advancing precision nerve-targeted treatments, today announced it will participate in the Virtual Investor Closing Bell Series on Thursday, May 22, 2025 at 4:00 PM ET. As part of the event, Brad Hauser, President and Chief Executive Officer of Autonomix, will provide a corporate overview and discuss the Company's first-in-class platform system technology, a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. In addition, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed. The live video webcast will be available on the Events page under the Investors section of the Company's website ( ). A webcast replay will be available two hours following the live event and will be accessible for 90 days. About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States. For more information, visit and connect with the Company on X, LinkedIn, Instagram and Facebook. Investor and Media Contact JTC Team, LLC Jenene Thomas (908) 824-0775 [email protected]
Yahoo
13-05-2025
- Business
- Yahoo
Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market
Discussion in Virtual Investor CEO Connect focuses on Company's planned follow-on market expansion study phase ('PoC 2') of proof-of-concept trial; Access Here Additional indications potentially double the addressable market beyond pancreatic cancer pain Follow-on expansion phase expected to begin in Q2 2025 THE WOODLANDS, TX, May 13, 2025 (GLOBE NEWSWIRE) -- – Autonomix Medical, Inc. (NASDAQ: AMIX) ('Autonomix' or the 'Company'), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today reiterated its plans for a follow-on phase to its proof-of-concept human clinical trial ('PoC 2') evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain. Additionally, the Company announced the release of a Virtual Investor CEO Connect segment discussing the PoC 2 phase. Access the segment here. As previously announced, based on the positive results demonstrated in the initial phase of the Company's first-in-human proof-of-concept trial ('PoC 1') in patients with severe pancreatic cancer pain, Autonomix will initiate the follow-on PoC 2 phase in a market expansion opportunity which has the potential to double the addressable market beyond pancreatic cancer pain by evaluating additional visceral cancers that signal pain through the Celiac Plexus and earlier stage pancreatic cancers with moderate to severe pain. The Company's PoC 2 phase is on track to commence in the second quarter of 2025. 'We are thrilled with the compelling results of our PoC 1 phase in late-stage pancreatic cancer patients, which demonstrated a significant reduction in pain, substantially decreased opioid use, and showed a meaningful improvement in quality of life for these patients. Building on this success, we are expanding our investigation to include gall bladder, liver, and bile duct cancers— effectively doubling our addressable potential market. This strategic expansion highlights the broad potential of our smart catheter technology and reinforces our commitment to transforming care for patients worldwide,' Brad Hauser, CEO of Autonomix commented. Autonomix's technology constitutes a platform with the potential to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. The PoC 2 phase will provide a concentrated focus on interventional cancer pain management applications like pancreatic, gall bladder, liver, and bile duct, with potential further expansion in oncology, gastroenterology, and other sectors where the Company has established key opinion leader relationships and emerging preclinical evidence. For more information about the Company's technology, please visit About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States. For more information, visit and connect with the Company on X, LinkedIn, Instagram and Facebook. Forward Looking Statements Some of the statements in this release are 'forward-looking statements,' which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the commencement of the PoC 2 phase of the trial. Such forward-looking statements can be identified by the use of words such as 'should,' 'might,' 'may,' 'intends,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'forecasts,' 'expects,' 'plans,' and 'proposes.' Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading 'Risk Factors' and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission ('SEC') on May 31, 2024 and in other filings made by us from time to time with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law. Investor and Media ContactJTC Team, LLCJenene Thomas908.824.0775autonomix@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
01-05-2025
- Business
- Associated Press
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor 'What This Means' Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase ('POC 1') where clinically meaningful pain reduction was demonstrated Outlines Company's plans to initiate market expansion study ('POC 2') into additional visceral cancers and earlier stage pancreatic cancer, expected to begin Q2 2025 Access the 'What This Means' video here THE WOODLANDS, TX, May 01, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ('Autonomix' or the 'Company'), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it recently participated in a Virtual Investor 'What This Means' segment. For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company's successfully met initial phase of the first-in-human proof-of-concept trial ('PoC 1') and the advancement to a follow-on phase ('PoC 2') evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain. The 'What This Means' video can be accessed here. About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States. For more information, visit and connect with the Company on X, LinkedIn, Instagram and Facebook. Investor and Media Contact JTC Team, LLC Jenene Thomas 908.824.0775 [email protected]
Associated Press
16-04-2025
- Business
- Associated Press
Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology
New patent underscores breadth of application and expansion opportunities for Company's catheter-based technology Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX, April 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ('Autonomix' or the 'Company'), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that European Patent Office (EPO) has granted Patent No. 3,226,792 (the '792) titled, ' Systems And Methods For Regulating Organ and/or Tumor Growth Rates, Function, and/or Development.' The granted '792 patent relates to the field of neuromodulation and covers a range of methods and systems used in nerve and receptor monitoring, electrophysiological monitoring, and surgical procedures related to the systems and mechanisms that regulate prostate and tumor growth. 'With the potential to address a wide range of conditions in which nerve activity plays a central role, we remain committed to strengthening our patent portfolio to support future applications and expansion opportunities. This European patent further validates the broad applicability of our technology across multiple conditions and anatomical targets. While our focus is on advancing development to reduce pancreatic cancer pain by targeting the celiac plexus, we believe our novel approach has the potential to address a broad array of peripheral nerve bundles associated with pain,' commented Brad Hauser, CEO of Autonomix. In particular, the methods and systems covered in the '792 patent may be used to sense, ablate and verify neurological traffic to and from the prostate and organs of the lower urinary tract (LUT) in order to slow, halt and/or reverse the growth of a prostate gland or a prostate tumor. Beyond prostate-related treatments, these systems and methods have potential applications in addressing various LUT diseases that share physiology of the prostatic plexus, including chronic prostatitis, hypogonadism, nocturia, and erectile dysfunction, by modulating neural activity and hormonal secretions of related organs. The Company is currently advancing its plans to submit an IDE and commence U.S. clinical trials in 2025 to support a labeling indication to commercialize the Autonomix Sensing and RF Ablation System in the U.S. as a treatment for pancreatic cancer pain. For more information about the Company's technology, please visit About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States. For more information, visit and connect with the Company on X, LinkedIn, Instagram and Facebook. Forward Looking Statements Some of the statements in this release are 'forward-looking statements,' which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential of the technology to treat cancerous tumors and the pain associated with pancreatic cancer. Such forward-looking statements can be identified by the use of words such as 'should,' 'might,' 'may,' 'intends,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'forecasts,' 'expects,' 'plans,' and 'proposes.' Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading 'Risk Factors' and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law. Investor and Media Contact JTC Team, LLC Jenene Thomas 908.824.0775 [email protected]
